JNJ-7706621

CAS No. 443797-96-4

JNJ-7706621( JNJ7706621 | JNJ 7706621 )

Catalog No. M14517 CAS No. 443797-96-4

A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 55 In Stock
5MG 96 In Stock
10MG 170 In Stock
25MG 268 In Stock
50MG 492 In Stock
100MG 690 In Stock
500MG 1395 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JNJ-7706621
  • Note
    Research use only, not for human use.
  • Brief Description
    A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
  • Description
    A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM), and no activity for Plk1 or Wee1; arrests the cell cycle at the G2-M phase; shows significant antitumor activity in tumor xenograft model.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    JNJ7706621 | JNJ 7706621
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    AuroraA|AuroraB|CDK1/CyclinB|CDK2/CyclinA|CDK2/CyclinE
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    443797-96-4
  • Formula Weight
    394.356
  • Molecular Formula
    C15H12F2N6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O
  • Chemical Name
    Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Emanuel S, et al. Cancer Res. 2005 Oct 1;65(19):9038-46. 2. Huang S, et al. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. 3. Seamon JA, et al. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
molnova catalog
related products
  • HSD992

    HSD992 is a potent, selective CDK2/3 inhibitor with moderate CDK9 inhibition with IC50 of 18 nM, 57 nM and 49 nM for CDK3/cyclin E, CDK2/cyclin A1 and CDK2/cyclin E, respecively.

  • ON123300

    ON123300 is a potent, multi-targeted kinase inhibitor with IC50 of 5, 3.9, 26, 26, 9.2 and 11 nM for ARK5, CDK4, PDGFRβ, FGFR1, RET and FYN, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.